Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Pregabalin Capsules from the United States Food and Drugs Administration to market a generic version of C.P. Pharmaceuticals C.V., LYRICA® (Pregabalin) capsules.
Drug-maker Lupin today said it has received tentative approval from the US health regulator to market Pregabalin capsules, used in the treatment of chronic pain as a result from an injury to the nervous system, in the American market.
Pharma major Lupin’s US subsidiary has got tentative approval from US Food and Drugs Administration (FDA) for its abbreviated new drug application (ANDA) for Pregabalin Capsules, used for treating pain caused by neurologic diseases and seizures.